Efficacy of Different Treatment Protocols in the Management of Malassezia Infected Dogs
DOI:
https://doi.org/10.48165/ijvsbt.19.6.03Keywords:
Dogs, Itraconazole conventional, Itraconazole pulse, Luliconazole topical, MalasseziaAbstract
Dogs presented to outpatient medicine unit, Veterinary College, Bengaluru, with clinical signs suggestive of Malassezia dermatitis were screened by cytological examination and these dogs comprised the study group. The present study was aimed to study the effectiveness of different treatment protocols such as conventional itraconazole, itraconazole pulse therapy and topical luliconazole therapy in Malassezia dermatitis in dogs. Dogs with clinical signs indicative of Malassezia dermatitis such as rancid odor, erythema, greasiness, hyperkeratinisation, hyperpigmentation and lichenification were subjected to cytological examination. Upon cytological examination, 24 dogs that were found positive for Malassezia spp were divided into three groups of eight dogs each. Skin swabs from these 24 dogs were cultured on Modified Dixon’s Agar (MDA) for the isolation of Malassezia spp. Treatment was done with lipophilic triazole antifungal, Itraconazole @5 mg/kg b. wt. sid, po for 21 days for group I and itraconazole @5mg/kg b wt po sid, two days in a week for three consecutive weeks for group II and topical imidazole antifungal luliconazole, for 21 days for group III. All the twenty four dogs were treated with systemic broad spectrum anti-bacterial cefadroxil @22 mg/kg b. wt. twice daily for 14 days and antihistamine, hydroxyzine @ 0.5 mg/kg bwt twice daily for 5 days with supportive care. The study proved that topical luliconazole and itraconazole pulse therapy are more effective clinically than conventional itraconazole on 21 day treatment regimen.
Downloads
References
Bhaswanth, K., Vivek Srinivas, V.M., Selvi, D., Antony, P.X., & Mukhopadhyay, H.K. (2019). Isolation and molecular characterization of Malassezia pachydermatis from otitis externa of dogs. Veterinary Research International, 7(3), 159-164.
Cafarchia, C., Iatta, R., Immediato, D., Puttilli, M.R., & Otranto, D. (2015). Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values. Medical Mycology, 53, 743-748.
Daniel, A.K., David, P.V., Ravishankar, C., & Sumith, K.S. (2022). Evaluation of different therapeutic protocols for canine malasseziosis. Indian Journal of Animal Health, 61(1), 71- 77.
Ganguly, C., Nambi, A.P., Srinivasan, S.R., Kavitha, S., & Balachandran, C. (2013). Pulse administration of itraconazole for the treatment of Malassezia dermatitis in dogs. Indian Veterinary Journal, 90(12), 96-97.
Glatz, M., Bosshard, P.P., Hoetzenecker, W., & Schmid-Grendelmeier, P. (2015). The role of Malassezia spp. in atopic dermatitis. Journal of Clinical Medicine, 4, 1217-1228.
Haimbach, B. (2019). Malassezia Dermatitis. In: Small Animal Dermatology for Technicians and Nurses. Wiley- Blackwell, pp. 45-52.
Hassan, S., & Ranjan, A. (2020). Therapeutic efficacy of topical luliconazole versus topical ketoconazole in the treatment of pityriasis versicolor patients: A hospital based comparative study. International Journal of Research in Dermatology, 6,
-252.
Khanna, D., & Bharti, S. (2014). Luliconazole for the treatment of fungal infections: An evidence-based review. Core Evidence, 24(9), 113-124.
Koga, H., Nanjoh, Y., Makimura, K., & Tssuboi, R. (2009). In vitro antifungal activities of luliconazole, a new topical Imidazole. Medical Mycology, 47, 640-647.
Marsella, R., Nicklin, C.F., & Nerbonne, J. (2000). Double-blind, placebo-controlled study to evaluate two miconazole conditioners for the treatment of Malassezia dermatitis in dogs. Veterinary Therapeutics, 1(3), 141-149.
Mueller, R.S., Bergvall, K., Bensignor, E., & Bond, R. (2012). A review of topical therapy for skin infections with bacteria and yeast. Veterinary Dermatology, 23(4), 330-362.
Nardoni, S., Dini, M., Taccini, F., & Mancianti, F. (2007). Occurrence, distribution and population size of Malassezia pachydermatis on skin and mucosae of atopic dogs. Veterinary Microbiology, 122(1-2), 172-177.
Pinchbeck, L.R., Hillier, A., Kowalski, J.J., & Kwochka, K.W. (2002). Comparison of pulse administration versus once daily administration of itraconazole for the treatment of Malassezia pachydermatis dermatitis and otitis in dogs. Journal of American Veterinary Medical Association, 220(12), 1807-1812.
Puig, L., Castella, G., & Cabanes, F.J. (2016). Cryptic diversity of Malassezia pachydermatis from healthy and diseased domestic animals. Mycopathologia, 181, 681-688.
Rathnapriya, N., UshaKrishnan, K., & Janaki, C. (2016). Isolation of Malassezia yeast using modified Dixon’s agar from pityriasis versicular lesions. Indian Journal of Basic Applied Medical Research, 5, 123-129.
Rincon, S., Cepero de Garc, M.C., & Espinel-Ingroff, A. (2006). A modified Christensen’s urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole. Journal of Clinical Microbiology, 44(9), 3429-3431.
Rubenstein, R.M., & Malerich, S.A. (2014). Malassezia (pityrosporum) folliculitis. Journal of Clinical and Aesthetic Dermatology, 7, 37-41.
Saunte, D.M.L., Gaitanis, G., & Hay, R.J. (2020). Malassezia-associated skin diseases, the use of diagnostics and treatment. Frontiers in Cellular and Infection Microbiology, 10, 112.
Selvi, D., Vijayalakshmi, P., Abiramy, A., Rajkumar, K., & Satishkumar, N. (2015). Malassezia dermatitis: A potential dermatological threat in dogs. Raksha Technical Review, 5, 16-19.
T hay ik k annu, A . B . , K in d o, A . J. , & Ve e r ar aghav an . M . (2015). Malassezia: Can it be ignored? Indian Journal of Dermatology, 60, 332-339.
Theelen, B., Cafarchia, C., Gaitanis, G., Bassukas, I.D., Boekhout, T., & Dawson, T.L. (2018). Malassezia ecology, pathophysiology, and treatment. Medical Mycology, 56, S10-S25.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Indian Journal of Veterinary Sciences & Biotechnology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.